Plain-English translation of NCT06959732 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a three-part treatment approach for people with follicular lymphoma who have never been treated before. The combination includes zanubrutinib, a targeted medication developed to fight blood cancer cells more precisely, plus two other drugs (an antibody called obinutuzumab and traditional chemotherapy drugs). Doctors hope this combination will work better than older treatments while causing fewer side effects.
Follicular lymphoma is a slow-growing but serious blood cancer that currently has no cure with standard treatments. The new treatment aims to improve how well the medication works while reducing the harmful side effects that come with traditional chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You will receive six cycles of treatment, with each cycle lasting 21 days. During each cycle, you will receive the medication combination either as infusions at a clinic or as pills at home, depending on the specific drug. Your doctor will check your response to treatment every two cycles with scans and blood tests. After the six cycles end, your doctors will do special testing to see if any cancer cells remain; if cancer cells are detected, you may continue taking zanubrutinib for up to 12 months as maintenance therapy, or you may receive standard maintenance care.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China